By Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator said on Friday, making the device the first of its kind to detect the brain-wasting condition.
Blood tests could speed up diagnosis of the disease and make it easier for more people to access its treatments such as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla, since traditional tests are often costly or uncomfortable.
Fujirebio’s test, branded as Lumipulse, checks for two proteins in the blood and uses their ratio to help detect signs of amyloid beta plaque, considered a hallmark of the disease, in the brain.
Other options to detect Alzheimer’s include procedures such as a spinal tap, which requires an invasive puncture to collect spinal fluid, or an expensive PET brain scan that may not be reimbursed by health insurers.
“Street expectations for both therapies (Leqembi and Kisunla) are modest” with a slow ramp over the next few years, given the lack of access to neurologists, said Citi analyst Geoffrey Meacham. “An approved blood-based diagnostic is a positive in a disease area that has been starved of game-changing innovation.”
Biogen has been doubling down on Leqembi but it has failed to live up to lofty expectations due to concerns over cost, efficacy and side effects.
In the first quarter, Leqembi brought $96 million in sales, while Lilly recorded $21.5 million in Kisunla sales.
Lumipulse and C2N Diagnostics’ PrecivityAD2 were the top two performers when compared with four other commercial blood tests for Alzheimer’s, according to a study led by researchers at Washington University School of Medicine.
Biogen has partnered with Fujirebio, and Eisai is collaborating with C2N to clinically advance and commercialize blood tests that can detect Alzheimer’s risk.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shreya Biswas, Shailesh Kuber and Shilpi Majumdar)
